study aimed at quantifying the test-retest reliability of HVPG in the specific context of RCTs for the treatment of PH in cirrhosis. Method: We performed a systematic search of published RCTs in patients with cirrhosis reporting individual patient-level data of HVPG at baseline and after an intervention, and that included a placebo or untreated control arm. Baseline and follow-up HVPG in the control groups were extracted after digitizing the plots. Test- retest reliability was estimated by the intraclass correlation coeffi- cient (ICC). Pooled ICC and potential associations with study characteristics were estimated with linear mixed models (patient and study as random effects). We considered ICC>0.75 as excellent as recommended for measures with physiological variability. Results: Seventeen trials including a total of 215 patients in the placebo/untreated groups had plots with legible individual HVPG changes. Time range between HVPGs was 20min to 730 days. Fig. A shows the association between baseline and follow-up HVPGs, and Fig. B the ICCs of individual studies.18% and 8% of the patients showed a ≥10% and ≥20% response, respectively. 11/17 studies showed excellent reliability (>0.75) of repeated HVPGs, and 5 showed moderate reliability. Only one study showed poor reliability (ICC: 0.14). In that study, a wedged catheter was used for HVPG measurement (as opposed to balloon catheter in the other 16 studies). Pooled ICC was excellent (0.88). We did not find an association between reliability and proportion of patients with alcohol-related liver disease, compensated vs decompensated cir- rhosis, multicentric vs single-center studies, year of publication or time between measurements. Conclusion: We show in this study that, in the context of RCTs, test- retest reliability of HVPG is excellent. We provide quantitative information on the range of expected reliability parameters, that will be useful for sample size calculation and results’ interpretation in trials with HVPG as an outcome measure. SAT237 Prognosis of alcoholic or viral B/C cirrhosis according to ABO blood group: results of abocirralvir, from CIRRAL and ANRS CO12 CirVir cohorts Isabelle Ollivier-Hourmand 1 , Pierre Nahon 2 , Cendrine Chaffaut 3 , Thong Dao 1 , Nga Nguyen 1 , Marcellin Patrick 4 , Dominique Roulot 5 , Victor de Lédinghen 6 , Stanislas Pol 7 , Dominique Guyader 8 , Isabelle Mabile-Archambeaud 9 , Fabien Zoulim 10 , Frédéric Oberti 11 , Albert Tran 12 , Jean-Pierre Bronowicki 13 , Louis Dalteroche 14 , Denis Ouzan 15 , Jean Marie Peron 16 , Jean-Pierre Zarski 17 , Marc Bourliere 18 , Dominique Larrey 19 , Alexandre Louvet 20 , Paul Cales 11 , Armand Abergel 21 , Philippe Mathurin 20 , Ariane Mallat 22 , Jean-Frédéric Blanc 6 , Eric Nguyen Khac 23 , Ghassan Riachi 24 , Laurent Alric 16 , Lawrence Serfaty 25 , Tereza Antonini 26 , Christophe Moreno 27 , Pierre Attali 28 , Dominique Thabut 29 , Christophe Pilette 30 , Jean Didier Grange 31 , Christine Silvain 32 , Nicolas Carbonell 33 , Brigitte Bernard Chabert 34 , Odile Goria 24 , Claire Wartelle-Bladou 35 , Romain Moirand 8 , Christos Christidis 36 , Gabriel Perlemuter 37 , Violaine Ozenne 38 , Jean Henrion 39 , Sophie Hillaire 40 , Vincent Di Martino 41 , Xavier Amiot 42 , Angela Sutton 43 , Nathalie Barget 44 , Yohann Repesse 45 , Sylvie Chevret 3 , Nathalie Ganne-Carrié 44 . 1 University Hospital, Hepatology, Caen, France; 2 University Hospital, Hepatology, Bondy, France; 3 University Hospital, Unité de Recherche Clinique (URC) Saint- Louis Lariboisie ̀ re Fernand-Widal, Paris, France; 4 University Hospital Beaujon, Hepatology, Clichy, France; 5 University Hospital Avicenne, Hepatology, Bobigny, France; 6 University Hospital, Hepatology, Bordeaux, France; 7 University Hospital Cochin, Hepatology, Paris, France; 8 University Hospital, Hepatology, Rennes, France; 9 university Hospital, Hepatology, Nantes, France; 10 University Hospital, Hepatology, Lyon, France; 11 University Hospital, Hepatology, Angers, France; 12 University Hospital, Hepatology, Nice, France; 13 University Hospital, Hepatology, Nancy, France; 14 University Hospital, Hepatology, Tours, France; 15 Institut arnault tzanck, Hepatology, Saint-Laurent-du-Var, France; 16 University Hospital, Hepatology, Toulouse, France; 17 University Hospital, Hepatology, Grenoble, France; 18 Hôpital Saint Joseph, Hepatology, Marseille, France; 19 University Hospital, Hepatology, Montpellier, France; 20 University Hospital, Hepatology, Lille, France; 21 University Hospital, Hepatology, Clermont Ferrand, France; 22 University Hospital Henri Mondor, Hepatology, Creteil, France; 23 University Hospital, Hepatology, Amiens, France; 24 University Hospital, Hepatology, Rouen, France; 25 University Hospital, Hepatology, Strasbourg, France; 26 University Hospital, Hepatology, Villejuif, France; 27 Hôpital Erasme, Hepatology, Bruxelles, Belgium; 28 University Hospital Paul Brousse, Hepatology, Villejuif, France; 29 University Hospital La Pitié Salpétrie ̀ re, Hepatology, Paris, France; 30 Centre Hospitalier Général, Hepatology, Le Mans, France; 31 University Hospital Tenon, Hepatology, Paris, France; 32 University Hospital, Hepatology, Poitiers, France; 33 University Hospital Saint Antoine, Hepatology, Paris, France; 34 University Hospital Saint Antoine, Hepatology, Reims, France; 35 Centre Hospitalier Général, Hepatology, Aix en Provence, France; 36 Institut Mutualiste Montsouris, Hepatology, Paris, France; 37 Hôpital Antoine Bécle ̀ re, Hepatology, Clamart, France; 38 University Hospital Saint Antoine, Hepatology, Paris, France; 39 Centre Hospitalier Jolimont- Lobbes, Hepatology, La Louviere, Belgium; 40 Hôpital Foch, Hepatology, Suresnes, France; 41 University Hospital, Hepatology, Besancon, France; 42 Hôpital Tenon, Hepatology, Paris, France; 43 University Hospital Jean Verdier, Laboratoire de Biochimie, Bondy, France; 44 University Hospital Jean Verdier, Hepatology, Bondy, France; 45 University Hospital, Hematology Laboratory, Caen, France Email: yoiojo@orange.fr Background and Aims: Non-O blood group (Non-O Gp) promotes deep vein thrombosis and venous thromboembolism recurrence in general population. Non-O Gp has also been associated with an increased risk of liver fibrosis in hepatitis C and hepatocellular carcinoma (HCC). The mechanism could be microthrombotic due to the decrease of ADAMTS 13 activity resulting in an increase of procoagulant factors VIII and Willebrand. These kinds of coagulation alterations are observed in case of cirrhosis. The aimwas to evaluate the influence of Non-O Gp on the prognosis of alcoholic or viral cirrhotic patients. Method: This is an observational study from CIRRAL et CIRVIR, 2 prospective cohorts of alcoholic and virological Child-Pugh A cirrhotic patients. The main criterion was the cumulated incidence of complications at 3 years with 2 composite criteria: « Decompensation » defined as at least one sign among: ascites, hydrothorax, encephalopathy, portal hypertension bleeding, biliru- bin >45 umol/l, spontaneous bacterial peritonitis and « Disease Progression » including a « Decompensation » or « the occurrence of one or more parameters » : PT < 45%, albumin <28 g/l, Child-Pugh aggravation, hepatorenal syndrome, non tumoral portal vein throm- bosis (NTPT), hepato-pulmonary syndrome, or pulmonary arterial hypertension. POSTER PRESENTATIONS S771 Journal of Hepatology 2020 vol. 73 | S653–S915